Anti-CD19 CAR-T cells therapy (Gustave Roussy, Cancer Campus, Grand Paris)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameAnti-CD19 CAR-T cells therapy (Gustave Roussy, Cancer Campus, Grand Paris)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicXerophthalmia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGustave Roussy, Cancer Campus, Grand Paris
China Registration ClassN/A

Develop Information

Active CompaniesGustave Roussy, Cancer Campus, Grand Paris
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicXerophthalmia +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A